FDA Awards Contract to AnaBios to Obtain DataFDA Awards Contract to AnaBios to Obtain Datafrom from Ex VivoEx Vivo Human Cardiac Platform Human Cardiac Platform

The FDA recently awarded AnaBios anexclusive Indefinite Delivery IndefiniteQuantity contract to utilize adult humanprimary tissues and cardiomyocytes fromorgan donors to assess drug safetyrelated to cardiac function.

“AnaBios is very honored to receive thiscontract from the FDA for this importantproject related to the cardiac safetyassessment of drugs,” said Dr. Paul E.Dr. Paul E.Mil ler, co-founder and ChiefMil ler, co-founder and ChiefCorporate Development Officer ofCorporate Development Officer ofAnaBiosAnaBios. “For over a decade, AnaBioshas worked diligently to develop a translational ex-vivo human heart platform. Weanticipate this collaboration will deliver critical data that could improve futureregulatory and pharmaceutical industry decision-making.”

READ FDA ANNOUNCEMENT

JCI Insight Publishes New Pain Paper Co-Authored byJCI Insight Publishes New Pain Paper Co-Authored byAnaBios ScientistsAnaBios Scientists

AnaBios scientists co-authored a recent JCIInsight article related to itch research titled,"Activation of Pruritogenic TGR5, MrgprA3,and MrgprC11 on Colon-Innervating AfferentsInduces Visceral Hypersensitivity."

The data in this study supports the existenceof an irritant-sensing system in the colon thatis a visceral representation of the itchpathways found in the skin, therebycontributing to sensory disturbancesaccompanying common intestinal disorders.

Click the button below to access the fullpublication.

READ JCI PUBLICATION

Circulation Research Publishes Meeting Notes from RecentCirculation Research Publishes Meeting Notes from RecentFDA Workshop on Improving Cardiotoxicity AssessmentFDA Workshop on Improving Cardiotoxicity Assessment

Circulation Research recently published thewhite paper from a recent FDA workshopfocused on improving cardiotoxicityassessment using human-relevant platforms.

The white paper concluded that there is anurgent need to integrate human-relevantplatforms and approaches into drugdevelopment to reduce liabilities surroundingthe cardiovascular safety of new therapeutics.

The FDA hosted the workshop to discussexisting gaps and challenges in translatingpreclinical cardiovascular safety data tohumans. The white paper summarized thetopics presented by speakers from academia,industry, and government, includingAnaBios' VP of Research &AnaBios' VP of Research &Development, Dr. Najah Abi-Gerges.Development, Dr. Najah Abi-Gerges.

DOWNLOAD WHITE PAPER

AnaBios CEO Accepts NCATS ASPIRE AwaAnaBios CEO Accepts NCATS ASPIRE Award to rd to DevelopDevelopPreclinical Pain Assays Using Human Sensory NeuronsPreclinical Pain Assays Using Human Sensory Neurons

AnaBios CEO Dr. Andre GhettiAnaBios CEO Dr. Andre Ghetti waspresented with the prestigious ASPIREASPIREDesign Chal lengeDesign Chal lenge award by Dr. JoniRutter, NCATS Deputy Director. AnaBioswon the award in the category, “BiologicalAssays for Translational Innovation inPain, Opioid Use Disorder andOverdose.”

Funds from the NCATS award will beused to study ex vivo human models ofpain for translational drug discovery.

READ ANNOUNCEMENT

SfN Poster: SfN Poster: Ex VivoEx Vivo Human Models of Extracellular Human Models of ExtracellularAcidification in Inflammatory Pain States for EnablingAcidification in Inflammatory Pain States for Enabling

Translational Research and Drug DiscoveryTranslational Research and Drug Discovery

AnaBios recently presented a newabstract, "Ex Vivo Human Models ofExtracellular Acidification inInflammatory Pain States forEnabling Translational Research &Drug Discovery" at the 2019 Societyfor Neuroscience annual meeting inChicago. The poster describes theuse of a novel preclinical discoverystrategy that relies on the ex vivointerrogation of human sensory neurons

isolated from organ donors to study the potential of new compounds to treat differenttypes of pain. Click the button below to download the poster.

DOWNLOAD POSTER

High-Quality Human Tissue for Biopharma &High-Quality Human Tissue for Biopharma &Academic ResearchAcademic Research

AnaBios ethically procures high-quality humantissue, including dorsal root ganglia, heart and

lung, from consented donors.

Our tissue preservation methodologies focuson perfusing human organ and tissue sampleswith solutions that temporarily inducemetabolic arrest and slow down thebiochemical processes responsible forischemic tissue damage. We offer both normaland diseased tissue, and provide demographicinformation, including sex, age and BMI.

Download one of our human tissue catalogstoday. For more information, contact us atinfo@anabios.cominfo@anabios.com.

DOWNLOAD CATALOGS